Having observed persistently low clozapine plasma levels, a decision was made to 'augment' clozapine with fluoxetine (an inhibitor of clozapine metabolism) 10 mg daily, further increased to 20 mg daily. Fluoxetine was subsequently replaced with fluvoxamine 50 mg daily (fluvoxamine is a more potent inhibitor of clozapine metabolism via CYP1A2). The introduction of fluvoxamine was preceded by a reduction in clozapine dosage to 600 mg/day. Two days after the first fluvoxamine administration JF developed a rash which only resolved once the drug was stopped.
Following this apparent allergic reaction, clozapine was titrated back to 900 mg/day and the histamine, H2 antagonist cimetidine (a moderately potent multi-enzyme inhibitor) was initiated at a dose of 800 mg/day. Five days after first cimetidine dose his clozapine plasma concentration was 0.47 mg/l and norclozapine 0.31 mg/l. This increase in plasma concentration was accompanied by a substantial clinical improvement which was sustained while the patient remained on both drugs and resulted in a transfer to a low-security hospital unit. At each stage of treatment the patient was kept fully informed of the reasons for prescribing enzyme inhibitors.
Clozapine metabolism
Unambiguously, clozapine has been demonstrated to be the most effective choice of treatment for refractory schizophrenia, acting against both positive and negative symptoms of the psychiatric disorder [Kane et al. 1988; Lewis et al. 2006; McEvoy et al. 2006 ].
Clozapine undergoes extensive hepatic first-pass metabolism via the CYP450 system, which results in the formation of two major metabolites, clozapine-N-oxide and N-desmethylclozapine (norclozapine), as well as three hydroxylated polar metabolites and protein-reactive derivatives [Pirmohamed et al. 1995] . The active N-desmethyl derivative, similarly to clozapine, exhibits very elaborate psychopharmacological binding properties but it is also more toxic to stem cells than its parent compound.
Both in vitro and in vivo studies have demonstrated that CYP1A2 plays the most significant role in clozapine disposition as it is the main catalyst in its oxidation and therefore the formation of norclozapine. Nonetheless, other CYP isoenzymes such as 3A4, 2D6, 2C9, 2C19, 2E1 have also been implicated in the drug's metabolism, et al. 2003; Fang et al. 1998; Ozdemir et al. 2001; Taylor 1997; Wetzel et al. 1998 ]. In vitro data suggest that other CYPs which are also involved in the formation of norclozapine are 2C19 and 3A4, with the latter also being the main enzyme mediating the formation of clozapine N-oxide [Eiermann et al. 1997; Olesen and Linnet 2001] .The importance of 2D6 has been questioned by many as no difference in clozapine's metabolite generation has been seen in 2D6 ultra-rapid metabolizers compared with slow metabolizers [Dahl et al. 1994 ]. The role of CYP 1A2 is confirmed by the observation that smoking (an inducer of CYP1A2) is associated with more rapid clozapine metabolism [Haring et al. 1989 ]
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Manipulation of plasma concentration
The correlation between clozapine plasma levels and response is well established. Levels above 0.35 mg/l are linked to a better response rate [Taylor et al. 2012 ]. Therefore, therapeutic plasma blood level monitoring when prescribing clozapine is considered beneficial.
Drug-level manipulation can be achieved by coadministering a substance which induces or inhibits enzyme(s) responsible for the metabolism of a drug. Fluvoxamine, a potent CYP1A2 inhibitor is sometimes added to clozapine treatment as a way of boosting its plasma concentration. This drug is useful in patients in whom CYP1A2 is induced by environmental factors (e.g. smoking) or where it is naturally expressed at constitutively high levels. It has been shown that adding fluvoxamine to clozapine treatment leads to a 5-to 12-fold increase in serum clozapine concentration [Chetty and Murray 2007; Heeringa et al. 1999] . Although usually beneficial, this interaction is potentially fatal given the magnitude of the clozapine plasma level elevation. The patient described in this case had an allergic reaction to fluvoxamine. As a result of this, a different and less-potent CYP1A2 inhibitor, cimetidine, was introduced. This histamine H2 antagonist is known to inhibit CYP1A2 [Martinez et al. 1999] as well as other isoenzymes such as 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4 [Burton et al. 2006; Preissner et al. 2010] . In this case, the addition of cimetidine to clozapine treatment led to an average of 1.9-fold increase in the clozapine level. There have been two previous reports of the concomitant use of cimetidine and clozapine [Sandson et al. 2007; Szymanski et al. 1991 ], but none for therapeutic purposes. In both cases clozapine level increased as a result of starting cimetidine.
An alternative to metabolic inhibition is to increase the dose of clozapine above the 900 mg daily maximum. This method is preferred by some because it allows slow titration against plasma levels. However, this unlicensed prescribing places the legal responsibility for adverse consequences on the prescriber. Moreover, it is an unusual practice and so might not be considered a prescribing practice likely to be undertaken by a competent practitioner, thus placing the prescriber in further legal peril.
This pharmacokinetic interaction between cimetidine and clozapine can be valuable for patients who are not suitable for treatment with an antidepressant or where adding a potent CYP1A2 inhibitor such as fluvoxamine would carry too much risk. Cimetidine might also be a useful treatment for the gastroesophageal reflux often seen with clozapine [Van Veggel et al. 2013] .
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